Cuban HIV vaccine to enter clinical trials

Clinical trials of a new recombinant HIV vaccine from Cuba are expected to begin soon, according to Enrique Iglesias, head of the vaccine development team, and Verena Muizo, director of clinical research at the Biotech and Genetic Engineering Center (CIGB), speaking at the International Biotech Conference-Havana 2012, according to AFP and Sky News. The vaccine, TERAVAC-HIV-1, has been tested in mice, and the next step is to carry out a small Phase I trial in HIV-positive people who have not yet progressed to AIDS. The trial is planned for the second or third quarter. Article | Story

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.